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DIABETES—Quality of Life Studies
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OBJECTIVES: The Cost Of Diabetes type 2 in Poland
(CODIP) study is the ﬁrst attempt aimed at valuating clin-
ical characteristics and Health Related Quality of Life
(HRQoL) associated with type 2 diabetes in Poland.
METHODS: We assessed quality of life of 303 patients
(mean age 61, mean time from diagnosis 10,86 year,
males 49%). Detailed information on quality of life was
collected with EuroQol-5D and Visual Analog Scale. The
inﬂuence of complications and therapeutic strategies on
quality of life was evaluated. The HRQoL score was ana-
lyzed as a function of number and type of complications
or therapeutic strategies, controlled for age, BMI and sex.
RESULTS: The strong relationship between HRQoL and
complications was observed. Patients without com-
plications reported mean HRQoL of 0.63 (95% CI:
0.59–0.68). The presence of microvascular or macrovas-
cular complications resulted in degresion of HRQoL to
0.55 (95% CI: 0.51–0.59) and 0.53 (95% CI: 0.49–0.58),
respectively. Both types of complications were associated
with the lowest HRQoL value: 0.44 (95% CI: 0.41–0.48).
Patients treated with diet and exercise only reported
quality of life equaled 0.61 (95% CI: 0.47–0.72), while
oral hypoglycemic drugs therapy decreased quality of life
to 0.57 (95% CI: 0.53–0.62). Insulin based therapy was
associated with the lowest quality of life scores: 0.46
(95% CI: 0.41–0.49) for monotherapy to 0.51 (95% CI:
0.47–0.54) for combined use of insulin and oral drugs.
The complications, but not treatment type, were found 
in multivariate analysis to be independent predictor of
HRQoL. CONCLUSIONS: Patients diabetes type 2’s
quality of life is affected by complications. Prevention of
complications may result in signiﬁcant improvement of
diabetic patients’ quality of life.
GASTROINTESTINAL DISEASES/DISORDERS
GASTROINTESTINAL DISORDERS—Clinical
Outcomes Studies
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AN EVIDENCE-BASED APPROACH PROVIDES 
A QUANTITATIVE ASSESSMENT OF THE
EFFICACY OF ESOMEPRAZOLE FOR HEALING
OF EROSIVE ESOPHAGITIS BASED ON DISEASE
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OBJECTIVE: Number needed to treat (NNT) provides
an estimate of the number of patients who need to be
treated with a drug to avoid an adverse outcome on alter-
nate therapy. This quantitative analysis focused on treat-
ment responses to proton pump inhibitors according 
to disease severity. METHODS: Efﬁcacy data from four
clinical trials using once-daily esomeprazole 40mg com-
pared with omeprazole 20mg (n = 3) and lansoprazole
30mg (n = 1) for treatment of erosive esophagitis (EE)
were identiﬁed. EE was graded A–D using the Los Angeles
(LA) classiﬁcation. For each trial we calculated the ther-
apeutic gain, the absolute risk reduction (ARR) and the
number needed to treat (NNT) for healing EE at week 8,
for all patients (LA Grades A–D) and separately for those
with severe disease (LA Grades C & D). RESULTS: For
all grades of esophagitis, the therapeutic gain achieved
with esomeprazole was 9.5%, 7.2% and 2.4% versus
omeprazole, and 3.8% versus lansoprazole. The NNT
with esomeprazole for severe disease ranged between 5
and 10 relative to omeprazole. The NNT with esomepra-
zole for severe disease was 8 relative to lansoprazole, indi-
cating that for every 8 patients treated with esomeprazole,
1 treatment failure with lansoprazole may be prevented.
CONCLUSIONS: Treatment with esomeprazole pro-
vided therapeutic gain regardless of the baseline severity
of EE compared with lansoprazole and omeprazole.
Because the severity of clinical symptoms is not predic-
tive of disease severity, treatment with the most effective
agent appears to be a rational therapeutic decision as sup-
ported in this evidence-based approach.
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A RETROSPECTIVE AUDIT OF PATIENTS
REDUCING PROTON PUMP INHIBITOR DOSE
TO LANSOPRAZOLE 15MG
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OBJECTIVES: NICE recommends the use of proton
pump inhibitors (PPIs) at the lowest effective dose in
patients with gastroesophageal reﬂux disease. Changing
patients from a standard or high dose PPI to esomepra-
zole 20mg has shown that only 5% (8/146) of patients
returned to a higher dose PPI in the subsequent 6 months.
The purpose of this study was to assess the frequency with
which patients who had reduced PPI dose to lansoprazole
15mg returned to a higher dose PPI. METHODS: A ret-
rospective audit of electronic patient records at 4 UK
general practices identiﬁed patients on continuous PPI
therapy at standard or high dose who had been switched
to lansoprazole 15mg and recorded any changes in PPI
therapy during the subsequent 6 months. RESULTS: The
audit identiﬁed 175 patients previously on regular (≥2 PPI
prescriptions in the previous 6 months) standard or high
dose PPI who had been changed to lansoprazole 15mg.
Within 6 months of the ﬁrst lansoprazole 15mg pre-
scription, 26% (46/175) of patients had changed back to
a higher dose PPI. Similar switch rates were obtained if
